Background Remnant-like lipoprotein particle cholesterol (RLP-C) is a highly atherogenic factor. RLP-C induces endothelial dysfunction and is associated with hyperinsulinemia. This study was designed to determine whether high plasma RLP-C levels predispose to the development of hypertension in subjects with normal blood pressure (BP).
Remnant-like lipoprotein particle cholesterol (RLP-C) derived from triglyceride-rich lipoprotein is taken up by macrophages and causes foam cell formation in vitro 1 and is considered to be highly atherogenic. [2] [3] [4] Elevated plasma RLP-C levels are associated with endothelial dysfunction [5] [6] [7] [8] [9] and hyperinsulinemia. 10, 11 Endothelial dysfunction and hyperinsulinemia may be associated with the development of hypertension. [12] [13] [14] Thus elevated plasma RLP-C levels may be associated with incident hypertension. In fact, elevated RLP-C was associated with hypertension in a general population without diabetes 15 and in patients with preeclampsia. 16 However, because of the cross-sectional nature of the previous studies, it was not clear whether high RLP-C levels in subjects with normal blood pressure (BP) is associated with incident hypertension. Accordingly, we conducted a longitudinal study in subjects in a general population without hypertension at baseline to evaluate the relationship between circulating RLP-C levels and incident hypertension.
Methods study population
A periodic epidemiological survey was performed in 1999 in a rural farming community located in the southwest part of Japan (Tanushimaru town). An earlier cohort in Tanushimaru was a part of the Seven Countries Study. 17 As reported previously, the demographic backgrounds of the subjects in this area were similar to those of the general Japanese population. 18 We examined 1,485 persons (602 men and 883 women) aged >40 years. We excluded from the analysis 678 subjects who had hypertension (BP ≥ 140/90 mm Hg), and/or were on antihypertensive medications or on antihyperlipidemic medications, and/or had RLP-C ≥ 100mg/dl (n = 2) at baseline.
A cross-sectional analysis was performed in 807 subjects. Ten years later, in 2009, we conducted a follow-up examination in the same cohort. Of 807 subjects, 65 (8.1%) had died, and 61 (7.6%) refused the re-examination. Consequently, 681 subjects (248 men and 433 women) were re-examined 10 years later and enrolled in this study.
data collection
A general medical history that included smoking, alcohol intake and current medication was obtained. Height and weight were measured, and body mass index was calculated as an index of obesity. Waist circumference was measured at the level of the umbilicus in the standing position. BP was measured twice with the subjects in the supine position. The second BP was adopted, and systolic and fifth-phase diastolic pressures were used for analysis. Blood was drawn from the antecubital vein in the morning after a 12-hour fast for determinations of lipids profiles (RLP-C, triglycerides, highdensity lipoprotein cholesterol, and low-density lipoprotein cholesterol), fasting plasma glucose, insulin, hemoglobin A1c, blood urea nitrogen, creatinine, von Willebrand factor, and fibrinogen levels. Fasting blood samples were centrifuged within 1 hour after collection. Creatinine was measured by enzymatic method. Von Willebrand factor was measured by a double-antibody enzyme-linked immunosorbent assay, and fibrinogen was measured by high-performance liquid chromatography. Serum RLP-C was measured by immuneseparation technique 19 (using an immune-affinity gel containing monoclonal antibodies to human apolipoprotein B-100 and apolipoprotein A-1). Five milligrams of antiapolipoprotein B-100 and anti-apolipoprotein A-1 immunoglobulin G each were coupled to 1 ml of CNBr-Sepharose 4B gel according to the recommendations of the manufacturer. Then the remaining active sites on the gels were blocked with 0.2 M glycine. Before use, the gels were conditioned with calf serum for 1 hour at room temperature with gentle shaking to reduce nonspecific binding and washed with 1.0 M acetic acid/0.5 M sodium chloride. This procedure was repeated twice. 19 Intra-and inter-assay coefficients of variation of RLP-C in the commercially available laboratory that performed the assays (Kyodo Igaku Laboratory, Fukuoka, Japan) were 7.6% and 7.8%, respectively. A homeostasis model assessment (HOMA) index (fasting plasma glucose (mg/dl) × insulin (μU/ml)/405) was calculated from fasting glucose and insulin levels as a marker of insulin resistance. 20 Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease (MDRD) study equation modified with a Japanese coefficient 21 : estimated glomerular filtration rate (ml/minute/1.73m 2 ) = 194 × Age −0.287 × serum creatinine −1.094 (if female, × 0.739). Hypertensive subjects were defined as those with BP ≥ 140/90 mm Hg and/ or those receiving antihypertensive medication.
This study was approved by the Tanushimaru branch of the Japan Medical Association and by the mayor, as well as by the ethics committee of Kurume University School of Medicine. All participants gave informed consent.
statistical analysis
Results are presented as means ± SDs, unless otherwise specified. Because of skewed distributions, natural logarithmic transformations were performed for RLP-C, triglycerides, insulin, and HOMA index. These variables were represented as original scale after analysis by log (natural) transformed values in tables. In Table 1, Table 2,  and Table 3 , values of RLP-C, triglycerides, insulin, and HOMA index are presented as geometric mean and range. The χ 2 test was used for categorical parameters to test differences between groups. Sex, smoking habits, and alcohol intake were used as dummy variables. Univariable logistic regression analysis was performed for factors related to the development of hypertension. We estimated odds ratios (ORs) and their 95% confidence intervals (CIs) per 1-unit (approximately 1 SD) increase in the variables. The ORs for RLP-C, triglycerides, insulin, and HOMA index are the OR per exponential (SD) time increase of the levels. Multiple logistic regression analysis was performed to determine independent parameters for development of hypertension after adjusting for age, sex, and confounding factors. Statistical significance was defined as P < 0.05. All statistical analyses were performed using the SAS system (version 9.3; SAS Institute, Cary, NC).
results Table 1 shows the baseline characteristics of the 681 normotensive subjects in 1999 stratified by sex. As is apparent from the table, the enrolled subjects had almost normal mean values of risk factors and other variables. Mean RLP-C level at baseline was 3.4 ± 1.8 mg/dl. RLP-C level was significantly higher (P < 0.01) in men than in women. Table 2 shows results of univariable and multivariable regression analyses for the cross-sectional correlates with baseline RLP-C levels. Multivariable analysis showed that HOMA index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (inversely), total cholesterol/highdensity lipoprotein cholesterol ratio, and triglycerides were significantly associated with RLP-C Table 3 shows univariable logistic regression analysis performed for predictors of the development of hypertension in 10 years. Age, male sex, RLP-C, systolic and diastolic BPs, body mass index, waist circumference, HOMA index, and triglycerides were significantly associated with the development of hypertension. Table 4 shows multivariable logistic regression analysis performed for predictors of the development of hypertension after adjustments for confounding factors. A significant (P = 0.04) OR for plasma RLP-C level was observed in the final model (model 5) [OR = 1.05, 95% CI = 1.00-1.10) for the development of hypertension (adjusted for baseline values of age, sex, systolic BP, body mass index, waist circumference, HOMA index, and triglycerides).
discussion
Based on known aspects of the function of plasma RLP-C, we hypothesized that a high level of RLP-C could predict the development of hypertension. RLP was an independent predictor for the development of hypertension after adjustments for other lipid profiles. Our results are consistent with our hypothesis that high levels of RLP-C were associated with the development of hypertension after 10 years in subjects that were normotensive at baseline. This study is the first to demonstrate a significant association between high plasma levels of RLP-C and the development of hypertension in a general population.
Several mechanisms could explain the association between RLP-C and development of hypertension. Because hypertension is associated with endothelial dysfunction and because preexisting endothelial function will precede hypertension, RLP-C-induced endothelial dysfunction may be one such mechanism. [5] [6] [7] [8] [9] To examine the contribution of endothelial dysfunction to the development of hypertension, we measured 2 serum markers of endothelial dysfunction, von Willebrand factor 22, 23 and fibrinogen. 24, 25 Our results demonstrated no contribution of these 2 factors (Table 3) .
However, from this study, we cannot rule out the possibility that endothelial dysfunction induced by RLP-C contributed to the development of hypertension because we had no data from more direct and reliable measures for endothelial dysfunction, such as responses to acetylcholine measured by the venous occlusion plethysmograph. [26] [27] [28] [29] Prospective studies 13, 14 have shown that increased insulin concentration predisposes to the development of hypertension. Hyperinsulinemia causes sympathetic activation by acting on the brain and impairs sodium secretion from the kidney, 30 leading to hypertension. 31 It has been reported that elevated RLP-C levels are associated with hyperinsulinemia or insulin resistance. 10, 11, 32, 33 In fact, our multivariable analysis of the baseline data demonstrated a significant association between RLP-C and HOMA index, a marker of insulin resistance (Table 2) . Thus, another possible explanation of the relationship between RLP-C and development of hypertension may be hyperinsulinemia or insulin resistance. In this study, Data are expressed as mean ± SD or %, unless otherwise indicated. eGFR was calculated by the Modification of Diet in Renal Disease (MDRD) study equation.
Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA 1c , NGSP, Glycosylated Hemoglobin A1c (National Glycohemoglobin Standardization Program); HOMA index, homeostasis model assessment index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RLP-C, remnant-like lipoprotein particle cholesterol; T-chol, Total cholesterol.
a Log-transformed values were used in analyses.
we determined baseline factors associated with the development of hypertension. Besides well-known factors such as age, BP, and obesity, hyperinsulinemia and/or insulin resistance were significant factors for the development of hypertension (Table 3) , consistent with previous reports. 13, 14, 34 Thus, our study appears to suggest that insulin resistance may underlie the association between RLP-C and the development of hypertension. However, our detailed analysis denied this possibility and suggested that RLP-C predicted the development of hypertension, independent of insulin resistance ( Table 4 ). The issue of lipid control and risk of hypertension is interesting. Meta-analysis of 20 randomized, controlled trials showed a small but statistically significant reduction of systolic BP with statin therapy. 35 Some review articles also supported the notion that statin may reduce blood pressure. 36, 37 Moreover, it was reported that bezafibrate reduced blood pressure in patients with hypertriglyceridemia. 38 Although it was not reported whether the blood pressure reduction was ascribed to RLP-C reduction, it may be feasible to consider that lipid-lowering therapy reduces blood pressure.
The limitations of our study are, first, 15.6% of the subjects were lost to follow-up because of death or refusal to participate in re-examination. Accordingly, we limited the analysis to subjects for whom all baseline and follow-up data were available. Second, the results of this study do not necessarily apply to other populations of different ethnicity. Third, we performed follow-up examination only once after 10 years. Thus we were not able to do Cox regression analysis. A final limitation was the lack of data of plasma RLP-C at follow-up. Nonetheless, this study suggests that plasma RLP-C plays a key role in the development of hypertension.
In conclusion, this study demonstrated that a high level of plasma RLP-C predicted the development of hypertension 10 years later in subjects normotensive at baseline. High level of plasma RLP-C may predispose to the development of hypertension.
acknowledgMents
This study was supported in part by the Kimura Memorial Heart Foundation, Fukuoka, by a Grant-in-Aid for Scientific Research from The Ministry of Education, Culture, Sports, Science and Technology, and by the Foundation for Total Health Promotion, Japan. We are grateful to the members of the Japan Medical Association of Ukiha, the elected officials and residents of Tanushimaru town, and the team of Abbreviations: BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA 1c (NGSP), Glycosylated Hemoglobin A1c (National Glycohemoglobin Standardization Program); HDL-C, high-density lipoprotein cholesterol; HOMA index, homeostasis model assessment index; LDL-C, low-density lipoprotein cholesterol; RLP-C, remnant-like lipoprotein particle cholesterol; SE, standard error; T-chol, total cholesterol. a These variables are shown in the original scale after analysis using log (natural)-transformed values. The odds ratios for these variables are the odds ratio per exponential (SD) time increase of the levels.
Bolded values are statistically significant. 
